[1]李杳瑶,刘 华,孙铜林,等.鳖甲煎丸对肝癌大鼠黏着斑激酶/雷帕霉素靶蛋白通路的影响[J].陕西中医,2024,(3):308-312.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.004]
　LI Yaoyao,LIU Hua,SUN Tonglin,et al.Effects of Biejia Jianwan on liver histopathological features and FAK/mTORC1 pathway in rats with hepatocellular carcinoma[J].,2024,(3):308-312.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.004]
点击复制

鳖甲煎丸对肝癌大鼠黏着斑激酶/雷帕霉素靶蛋白通路的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年3期
页码:
308-312
栏目:
基础研究
出版日期:
2024-03-05

文章信息/Info

Title:
Effects of Biejia Jianwan on liver histopathological features and FAK/mTORC1 pathway in rats with hepatocellular carcinoma
作者:
李杳瑶1; 刘 华1; 孙铜林1; 伍 静1; 孟小莎1; 伍梦思1; 2; 苏联军2
(1.湖南中医药大学第一附属医院,湖南 长沙 410007; 2.湖南中医药大学,湖南 长沙 410208)
Author(s):
LI Yaoyao; LIU Hua; SUN Tonglin; WU Jing; MENG Xiaosha; WU Mengsi; SU Lianjun
(The First Hospital of Hunan University of Chinese Medicine,Changsha 410007,China)
关键词:
肝癌;  鳖甲煎丸;  斑激酶;  雷帕霉素靶蛋白;  肝癌组织重量;  抑瘤率
Keywords:
Liver cancer;  Biejia Jianwan;  Spot kinase;  Rapamycin target protein;  Liver cancer tissue weight;  Tumor inhibition rate
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7369.2024.03.004
文献标志码:
A
摘要:
目的:探讨鳖甲煎丸对肝癌模型大鼠肝组织病理特征及FAK/mTORC1通路的影响。方法:HepG2(1×107)细胞注射于大鼠右腋皮下,建立肝癌模型,分为模型组、5-氟尿嘧啶组、鳖甲煎丸低剂量组、鳖甲煎丸高剂量组,另设正常组。各药物组给予相应药物灌胃,持续给药4周,正常组、模型组给予等体积的0.9%氯化钠溶液。实验结束后,测定肝癌组织重量、肝癌组织体积、肝癌组织抑瘤率、肝癌FAK、mTORC1水平、肝癌VEGFR-2、VEGF、IL-4、IL-8、TNF-α蛋白水平。结果:与正常组比较,模型组肝癌组织重量、肝癌组织体积、肝癌组织抑瘤率、VEGFR-2、VEGF、IL-4、IL-8、TNF-α蛋白、肝癌FAK、mTORC1 mRNA和蛋白表达升高(均P<0.05)。与模型组比较,5-氟尿嘧啶组、鳖甲煎丸低剂量组、鳖甲煎丸高剂量组肝癌组织重量、肝癌组织体积、肝癌组织抑瘤率、VEGFR-2、VEGF、IL-4、IL-8、TNF-α蛋白、肝癌FAK、mTORC1 mRNA和蛋白表达降低(均P<0.05)。鳖甲煎丸高剂量组肝癌组织重量、肝癌组织体积、肝癌组织抑瘤率、VEGFR-2、VEGF、IL-4、IL-8、TNF-α蛋白、肝癌FAK、mTORC1 mRNA和蛋白表达低于鳖甲煎丸低剂量组(均P<0.05)。结论:鳖甲煎丸对大鼠肝癌具有明显抑制作用,能减轻大鼠肝癌所致的病理损伤,其机制可能与鳖甲煎丸抑制肝癌FAK、mTORC1表达,诱导肝癌细胞凋亡,降低炎症反应有关。
Abstract:
Objective:To explore effect of Biejia Jianwan on liver histopathological features and FAK/mTORC1 pathway in rats with hepatocellular carcinoma.Methods:HepG2(1×107)cells were injected subcutaneously into the right armpit of rats to establish liver cancer model,which were divided into model control group,5-fluorouracil group,Biejia Jianwan low-dose group and Biejia Jianwan high-dose group,and a normal control group.Each drug group were given corresponding drugs administered intragastrically for 4 weeks,and the normal group and the model control groups were given equal volumes of normal saline.After the test,liver cancer tissue weight,liver cancer tissue volume,liver cancer tissue tumor inhibition rate,liver cancer FAK and mTORC1 levels,and liver cancer VEGFR-2,VEGF,IL-4,IL-8,and TNF-α protein levels were measured.Results:Compared with the normal control group,liver cancer tissue weight,liver cancer tissue volume,tumor inhibition rate,VEGFR-2,VEGF,IL-4,IL-8,TNF-α protein,liver cancer FAK,mTORC1 mRNA and protein expression in the model group were increased(all P<0.05).Compared with the model group,liver cancer tissue weight,liver cancer tissue volume,liver cancer tumor inhibition rate,VEGFR-2,VEGF,IL-4,IL-8,TNF-α protein,liver cancer FAK,mTORC1 mRNA and protein expression decreased in the 5-fluorouracil group,Biejia Jianwan low-dose group and Biejia Jianwan high-dose group(all P<0.05).Liver cancer tissue weight,liver cancer tissue volume,tumor inhibition rate,VEGFR-2,VEGF,IL-4,IL-8,TNF-α protein,liver cancer FAK,mTORC1 mRNA and protein expression in Biejia Jianwan high-dose group were lower than those in the Biejia Jianwan low-dose group(all P<0.05).Conclusion:Biejia Jianwan has obvious inhibitory effect on liver cancer in rats,and can reduce pathological damage caused by liver cancer in rats.Biejia Jianwan can inhibit expression of FAK and mTORC1 in liver cancer cells,induce apoptosis and reduce inflammatory response in liver cancer cells.

参考文献/References:

[1] PAUL B,LEWINSKA M,ANDERSEN J B.Lipid alterations in chronic liver disease and liver cancer[J].Journal of High Energy Physics,2022,4(6):100479.
[2] AHMADIAN E,JANAS D,EFTEKHARI A,et al.Application of carbon nanotubes in Sensing/Monitoring of pancreas and liver cancer[J].Chemosphere,2022,30(2):134826.
[3] CHENG K,CAI N,ZHU J,et al.Tumor-associated macrophages in liver cancer:From mechanisms to therapy[J].Cancer Communications,2022,42(11):1112-1140.
[4] 孔德军,周清华.黏着斑激酶——肿瘤治疗的新靶点[J].中国肺癌杂志,2005,8(3):243-246.
[5] 李亮亮.mTOR抑制剂雷帕霉素的抗肿瘤作用[J].海南医学,2019,30(2):241-244.
[6] 王光辉,王虎霞,陈楠,等.MMP-2在乳腺癌中的表达及临床意义[J].陕西医学杂志,2017,46(11):1516-1519.
[7] WU Y J,LIN S H,DIN Z H,et al.Sinulariolide inhibits gastric cancer cell migration and invasion through downregulation of the EMT process and suppression of FAK/PI3K/AKT/mTOR and MAPKs signaling pathways[J].Marine Drugs,2019,17(12):668.
[8] 贺松其,程旸,朱云,等.鳖甲煎丸对肝细胞癌中 Wnt/β-catenin信号通路及抑制基因 DKK-1、FrpHe 表达的影响[J].南方医科大学学报,2013,33(1):30-33.
[9] 陈达理,张绪慧.鳖甲煎丸抗肿瘤血管生成的实验研究[J].浙江中医杂志,2004,39(12):535-537.
[10] 贺松其,姚飞龙,程旸,等.鳖甲煎丸抗肝癌转移的理论依据及分子机制探讨[J].中华中医药杂志,2011,26(11):2579-2581.
[11] 孙海涛,贺松其,文彬,等.鳖甲煎丸对肝癌细胞中 Wnt 信号分子 β-catenin、GSK-3β 及靶基因 CD44v6、VEGF 的影响[J].南方医科大学学报,2014,34(10):1454-1458.
[12] 孙海涛,贺松其,文彬,等.鳖甲煎丸对 HepG2 裸鼠移植瘤 Wnt 信号通路相关分子及靶基因的影响[J].中国实验方剂学杂志,2016,22(13):81-85.
[13] 黄鸿娜,黄晶晶,毛德文,等.鳖甲煎丸对大鼠肝癌癌前病变血管生成和微环境的机制探讨[J].时珍国医国药,2016,27(11):2570-2572.
[14] 文彬,孙海涛,贺松其,等.鳖甲煎丸对 HepG2 裸鼠移植瘤的抑制作用及瘤体组织中 β-catenin、Tbx3 表达水平的影响[J].南方医科大学学报,2016,36(2):210-214.
[15] 孙嘉玲,文彬,杨雪梅,等.基于 PI3K/AKT/GSK-3β 信号通路探讨鳖甲煎丸调控肝癌细胞 Hep3B 增殖转移的机制[J].中华中医药杂志,2021,36(3):1361-1365.
[16] SIU M K Y,JIANG Y X,WANG J J,et al.Hexokinase 2 regulates ovarian cancer cell migration invasion and stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 signaling cascades[J].Cancers,2019,11(6):813.
[17] 李凯.5-氟尿嘧啶预防翼状胬肉85例术后复发作用观察[J].陕西医学杂志,2012,41(9):1264.
[18] 许晓梅,毛惠云,韩芳琦. 5-氟尿嘧啶在青光眼滤过性手术后的应用[J].陕西医学杂志,2002,31(11):1013-1014.
[19] 郑迪,孙强. 5-氟尿嘧啶联合TACE治疗原发性肝癌的效果[J].癌症进展,2018,16(11):1379-1381,1415.
[20] 万丹,蔡萍,张水寒.土鳖虫超微粉体中尿嘧啶、次黄嘌呤的含量测定[J].湖南中医药大学学报,2011,31(9):36-37,40.
[21] 郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析[J].陕西医学杂志,2019,48(7):850-852.
[22] 陈霞,张国尊,刘莹莹,等.巨噬细胞与肝癌转移及临床预后关系研究[J].陕西医学杂志,2018,47(3):292-294.
[23] 陈建卫,高娟,朱忠辉,等.黄连素对肝癌细胞系 HepG2 细胞体外迁移影响及其机制研究[J].陕西医学杂志,2018,47(6):686-689.
[24] 周雪涛,冯伟静.注射用白眉蛇毒血凝酶局部应用对 PPH 术出血疗效的观察[J].陕西医学杂志,2018,47(10):1346-1348.
[25] 段惠龙.不同介入栓塞化疗方案联合射频消融治疗原发性肝癌疗效及对患者免疫功能的影响[J].陕西医学杂志,2018,47(10):1303-1305.

相似文献/References:

[1]肖 岚,朱 宏,张 婷,等.董克礼教授治疗原发性肝癌临床经验*[J].陕西中医,2020,(11):1639.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.032]
　XIAO Lan,ZHU Hong,ZHANG Ting,et al.Experience of professor DONG Keli for treating primary liver cancer[J].,2020,(3):1639.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.032]
[2]王 军,徐建良,杜燕红.扶正祛邪汤对肝癌模型大鼠肠道菌群微生态环境的作用研究[J].陕西中医,2021,(2):143.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.002]
　WANG Jun,XU Jianliang,DU Yanhong.Effect of Fuzheng Quxie decoction on intestinal microflora microecological environment of liver cancer model rats[J].,2021,(3):143.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.002]
[3]朱玉辉,柴 劲.黄芪补气汤联合还原型谷胱甘肽对肝癌介入治疗后患者肝功能、氧化应激及炎症的影响[J].陕西中医,2021,(5):570.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.006]
　ZHU Yuhui,CHAI Jin.Effect of Huangqi Buqi decoction combined with reduced glutathione on liver function,oxidative stress and inflammation after interventional therapy for hepatocellular carcinoma[J].,2021,(3):570.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.006]
[4]刘振方,孙巧玉,孟祥彩,等.黄芩素下调微小RNA-130a抑制肝癌细胞侵袭机制研究[J].陕西中医,2021,(12):1667.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.003]
　LIU Zhenfang,SUN Qiaoyu,MENG Xiangcai,et al.Study on mechanism of baicalein down-regulating miR-130a to inhibit hepatocellular carcinoma invasion[J].,2021,(3):1667.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.003]
[5]周 翔,顾 达,童 聪,等.鳖甲煎丸对CCl4诱导小鼠肝纤维化的治疗作用机制研究[J].陕西中医,2022,(2):151.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.003]
　ZHOU Xiang,GU Da,TONG Cong,et al.Therapeutic mechanism of Biejiajian pills on mice model of liver fibrosis induced by CCl4[J].,2022,(3):151.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.003]
[6]李武浩,许尤琪.中医药防治肝动脉灌注化疗相关不良反应研究进展[J].陕西中医,2022,(5):673.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.031]
　LI Wuhao,XU Youqi.Clinical research progress of traditional Chinese medicine on the prevention and treatment of related adverse reaction of hepatic artery infusion chemotherapy[J].,2022,(3):673.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.031]
[7]陈 嵘,李淑敏,李旭华,等.软坚散结方调控小鼠HIF-1α 糖酵解分子转导抑制肝肿瘤细胞增殖机制研究[J].陕西中医,2023,(7):839.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.003]
　CHEN Rong,LI Shumin,LI Xuhua,et al.Mechanism study on Ruanjian Sanjie prescription inhibit proliferation of liver cancer cells through regulating HIF-1α pathway[J].,2023,(3):839.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.003]
[8]刘 鹏,陈青山,杨建波.柴胡疏肝散加减联合射频消融治疗肝癌疗效研究[J].陕西中医,2023,(7):892.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.015]
　LIU Peng,CHEN Qingshan,YANG Jianbo.Curative effect study on Chaihu Shugan powder combined with radiofrequency ablation for liver cancer[J].,2023,(3):892.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.015]
[9]张宏生,林月洁,陆凤娟.血府逐瘀汤加减联合盐酸吗啡缓释片治疗肝癌疼痛瘀血内阻证疗效研究[J].陕西中医,2023,(7):897.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.016]
　ZHANG Hongsheng,LIN Yuejie,LU Fengjuan.Clinical study on modified Xuefu Zhuyu decoction supplemented with morphine hydrochloride sustained-release tablets in treatment of liver cancer pain of Yuxue Neizu syndrome[J].,2023,(3):897.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.016]
[10]孔庆旭,陈桂云,陈自力,等.槲芪方加减对肝癌化疗栓塞术后大鼠一氧化氮合酶、血管内皮生长因子、乏氧及免疫功能的影响[J].陕西中医,2024,(2):181.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.007]
　KONG Qingxu,CHEN Guiyun,CHEN Zili,et al.Effects of Huqi formula on iNOS,VEGF,hypoxia and immune function of rats after chemoembolization for liver cancer[J].,2024,(3):181.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.007]

备注/Memo

备注/Memo:
基金项目:湖南省自然科学基金资助项目(2021JJ30523); 湖南省中医肿瘤临床医学研究中心项目(2021SK4023)
更新日期/Last Update: 2024-03-08